Top

Current Cardiovascular Imaging Reports

Published in:

Open Access 08-05-2024 | Sarcoidosis | Review

Insights of Inflammatory Heart Involvement in Cardiac Sarcoidosis – A Systemic Review

Authors: Julia Treiber, Christian W. Hamm, Samuel T. Sossalla, Andreas Rolf

Published in: Current Cardiovascular Imaging Reports | Issue 7/2024

Abstract

Purpose of the Review

The purpose of this paper is to review the current knowledge regarding imaging inflammation in cardiac sarcoidosis (CS).

Recent Findings

Noninvasive imaging methods like cardiac magnetic resonance (CMR) and 18-fluorodeoxyglucose (¹⁸FDG) positron-emission tomography-computed tomography (PET-CT) scans have emerged as the most important modalities in diagnosing and monitor therapy efficacy in CS. The differentiation between an active and a chronic, silent clinical state is crucial for decision making. T1- and T2-mapping by CMR provide a unique opportunity to discriminate normal and diseased myocardium by detecting myocardial edema and fibrosis. While T1-mapping is sensitive to fibrosis and edema, T2 is primarily influenced by tissue water content. Increased 18-fluorodeoxyglucose (¹⁸FDG) uptake in positron-emission tomography-computed tomography (PET-CT) scan is a hallmark feature of CS and defines active inflammation. Therefore, the hybrid application of both CMR and ¹⁸FDG-PET-CT scans has evolved as the standard procedure to detect CS and monitor the therapeutic response.

Summary

Imaging inflammation in CS is basically performed by CMR T2-mapping and ¹⁸FDG uptake in PET-CT scan. Both are reliable methods in identifying active CS and follow up therapy and can be used synergistically. Additionally CMR provides further prognostic insights by late gadolinium enhancement that increases the risk for malignant arrhythmia and for relapse after therapy weaning.

Ekström K, Lehtonen J, Nordenswan H-K, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. Eur Heart J. 2019;40:3121–8. https://doi.org/10.1093/eurheartj/ehz428.CrossRefPubMed

Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac Sarcoidosis. J Am Coll Cardiol. 2016;68:411–21. https://doi.org/10.1016/j.jacc.2016.03.605.CrossRefPubMed

Patel MR, Cawley PJ, Heitner JF, et al. Detection of Myocardial Damage in Patients with Sarcoidosis. Circulation. 1969;2009:120. https://doi.org/10.1161/CIRCULATIONAHA.109.851352.CrossRef

Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119:167–72.PubMed

Tschöpe C, Cooper LT, Torre-Amione G, Van Linthout S. Management of Myocarditis-Related Cardiomyopathy in Adults. Circ Res. 2019;124:1568–83. https://doi.org/10.1161/CIRCRESAHA.118.313578.CrossRefPubMed

Leone O, Veinot JP, Angelini A, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21:245–74. https://doi.org/10.1016/j.carpath.2011.10.001.CrossRefPubMed

Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–48. https://doi.org/10.1093/eurheartj/eht210.CrossRefPubMed

Tschöpe C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18:169–93.CrossRefPubMed

Krejci J, Mlejnek D, Sochorova D, Nemec P. Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment. BioMed Res Int. 2016:1–11. https://doi.org/10.1155/2016/4087632.

10.

Korosoglou G, Giusca S, Montenbruck M, et al. Fast Strain-Encoded Cardiac Magnetic Resonance for Diagnostic Classification and Risk Stratification of Heart Failure Patients. JACC Cardiovasc Imaging. 2021;14:1177–88. https://doi.org/10.1016/j.jcmg.2020.10.024.CrossRefPubMed

11.

Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–65. https://doi.org/10.1056/NEJMra071714.CrossRefPubMed

12.

Okada DR, Bravo PE, Vita T, et al. Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. J Nucl Cardiol. 2018;25:1136–46. https://doi.org/10.1007/s12350-016-0658-1.CrossRefPubMed

13.

Birnie DH, Sauer WH, Bogun F, et al. HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis. Heart Rhythm. 2014;11:1304–23. https://doi.org/10.1016/j.hrthm.2014.03.043.CrossRef

14.

Terasaki F, Azuma A, Anzai T, et al. JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis. Circ J. 2019;83:2329–88. https://doi.org/10.1253/circj.CJ-19-0508.CrossRefPubMed

15.

Kusano KF, Satomi K. Diagnosis and treatment of cardiac sarcoidosis. Heart (British Cardiac Society). 2016;102:184–90. https://doi.org/10.1136/heartjnl-2015-307877.CrossRefPubMed

16.

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368.CrossRefPubMed

17.

• Kouranos V, Tzelepis GE, Rapti A, et al. Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2017;10:1437–47. https://doi.org/10.1016/j.jcmg.2016.11.019. This paper demonstrates, that CMR is the most valuable diagnostic test compared to electrocardiography and echogardiography to diagnose CS and provides prognostic information.CrossRefPubMed

18.

Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am College Cardiol. 2018:72. https://doi.org/10.1016/J.JACC.2018.09.072.

19.

Aitken M, Chan MV, Urzua Fresno C, et al. Diagnostic Accuracy of Cardiac MRI versus FDG PET for Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis. Radiology. 2022;304:566–79. https://doi.org/10.1148/radiol.213170.CrossRefPubMed

20.

Waki H, Eguchi K, Toriumi S, et al. Isolated Cardiac Sarcoidosis Mimicking Arrhythmogenic Right Ventricular Cardiomyopathy. Int Med (Tokyo, Japan). 2018;57:835–9. https://doi.org/10.2169/internalmedicine.9395-17.CrossRef

21.

Narula N, Iannuzzi M. Sarcoidosis: Pitfalls and Challenging Mimickers. Front Med. 2020;7:594275. https://doi.org/10.3389/fmed.2020.594275.CrossRef

22.

Oyama-Suzuki K, Fukushima K, Egi R, et al. Cardiac Sarcoidosis Mimicking Anterior Myocardial Infarction. Ann Nucl Cardiol. 2021;7:73–6. https://doi.org/10.17996/anc.21-00136.CrossRefPubMedPubMedCentral

23.

• Pöyhönen P, Nordenswan H-K, Lehtonen J, et al. Cardiac magnetic resonance in giant cell myocarditis: a matched comparison with cardiac sarcoidosis. Eur Heart J - Cardiovasc Imaging. 2023;24:404–12. https://doi.org/10.1093/ehjci/jeac265. This paper indicates that CS can mimic other cardiac diseases espacially giant cell myocarditis.CrossRefPubMedPubMedCentral

24.

Takemura K, Nakamura R, Shimazu K, et al. A case of cardiac sarcoidosis mimicking cardiac amyloidosis on cardiovascular magnetic resonance. ESC Heart Fail. 2018;5:306–10. https://doi.org/10.1002/ehf2.12263.CrossRefPubMedPubMedCentral

25.

Bobbio E, Bollano E, Oldfors A, et al. Phenotyping of giant cell myocarditis versus cardiac sarcoidosis using cardiovascular magnetic resonance. Int J Cardiol. 2023;387:131143. https://doi.org/10.1016/j.ijcard.2023.131143.CrossRefPubMed

26.

Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26:1461–74. https://doi.org/10.1093/eurheartj/ehi258.CrossRefPubMed

27.

Smedema J-P, Snoep G, van Kroonenburgh MPG, et al. Evaluation of the Accuracy of Gadolinium-Enhanced Cardiovascular Magnetic Resonance in the Diagnosis of Cardiac Sarcoidosis. J Am Coll Cardiol. 2005;45:1683–90. https://doi.org/10.1016/j.jacc.2005.01.047.CrossRefPubMed

28.

Flamée L, Symons R, Degtiarova G, et al. Prognostic value of cardiovascular magnetic resonance in patients with biopsy-proven systemic sarcoidosis. Eur Radiol. 2020;30:3702–10. https://doi.org/10.1007/s00330-020-06765-1.CrossRefPubMed

29.

Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501–11. https://doi.org/10.1016/j.jcmg.2012.10.021.CrossRefPubMed

30.

Agoston-Coldea L, Kouaho S, Sacre K, et al. High mass (>18g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. Int J Cardiol. 2016;222:950–6. https://doi.org/10.1016/j.ijcard.2016.07.233.CrossRefPubMed

31.

Magnocavallo M, Vetta G, Polselli M, et al. “Function follows form”: Role of cardiac magnetic resonance for ventricular arrhythmia risk stratification in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2023;34:1781–4. https://doi.org/10.1111/jce.16020.CrossRefPubMed

32.

•• Stevenson A, Bray JJH, Tregidgo L, et al. Prognostic Value of Late Gadolinium Enhancement Detected on Cardiac Magnetic Resonance in Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2023;16:345–57. https://doi.org/10.1016/j.jcmg.2022.10.018. In this meta-analysis of Stevenson et al. late gadolinum enhancement results in increased odds of ventricular arrhythmia and all-cause mortality with additional prognostic information in case of biventricular involvement.CrossRefPubMed

33.

• Gowani Z, Habibi M, Okada DR, et al. Utility of Cardiac Magnetic Resonance Imaging Versus Cardiac Positron Emission Tomography for Risk Stratification for Ventricular Arrhythmias in Patients With Cardiac Sarcoidosis. Am J Cardiol. 2020;134:123–9. https://doi.org/10.1016/j.amjcard.2020.08.007. This work showed that late gadolinum enhancement is one of the most important features to predict ventricular arrhythmia and is superior to inflammation in ¹⁸18FDG PET-CT.CrossRefPubMed

34.

Velangi PS, Chen K-HA, Kazmirczak F, et al. Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis. JACC Cardiovasc Imaging. 2020;13:1395–405. https://doi.org/10.1016/J.JCMG.2019.12.011.CrossRefPubMedPubMedCentral

35.

• Wang J, Zhang J, Hosadurg N, et al. Prognostic Value of RV Abnormalities on CMR in Patients With Known or Suspected Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2023;16:361–72. https://doi.org/10.1016/j.jcmg.2022.11.012. This work highlights the prognostic importance to monitor and assess RV abnormalitiesCrossRefPubMed

36.

Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92. https://doi.org/10.1186/1532-429X-15-92.CrossRefPubMedPubMedCentral

37.

Haaf P, Garg P, Messroghli DR, et al. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016;18:89. https://doi.org/10.1186/s12968-016-0308-4.CrossRefPubMedPubMedCentral

38.

Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imagi. J Cardiovasc Magn Reson. 2017;19:75. https://doi.org/10.1186/s12968-017-0389-8.CrossRefPubMedPubMedCentral

39.

Greulich S, Ferreira VM, Dall’Armellina E, Mahrholdt H. Myocardial Inflammation-Are We There Yet? Curr Cardiovasc Imaging Rep. 2015;8:6. https://doi.org/10.1007/s12410-015-9320-6.CrossRefPubMedPubMedCentral

40.

O’Brien AT, Gil KE, Varghese J, et al. T2 mapping in myocardial disease: a comprehensive review. J Cardiovasc Magn Reson. 2022;24:33. https://doi.org/10.1186/s12968-022-00866-0.CrossRefPubMedPubMedCentral

41.

Spieker M, Katsianos E, Gastl M, et al. T2 mapping cardiovascular magnetic resonance identifies the presence of myocardial inflammation in patients with dilated cardiomyopathy as compared to endomyocardial biopsy. Eur Heart J - Cardiovasc Imaging. 2018;19:574–82. https://doi.org/10.1093/ehjci/jex230.CrossRefPubMed

42.

Pezel T, Viallon M, Croisille P, et al. Imaging Interstitial Fibrosis, Left Ventricular Remodeling, and Function in Stage A and B Heart Failure. JACC Cardiovasc Imaging. 2021;14:1038–52. https://doi.org/10.1016/j.jcmg.2020.05.036.CrossRefPubMed

43.

Moustafa A, Khan MS, Alsamman MA, et al. Prognostic significance of T1 mapping parameters in heart failure with preserved ejection fraction: a systematic review. Heart Fail Rev. 2021;26:1325–31. https://doi.org/10.1007/s10741-020-09958-4.CrossRefPubMed

44.

•• Puntmann VO, Isted A, Hinojar R, et al. T1 and T2 Mapping in Recognition of Early Cardiac Involvement in Systemic Sarcoidosis. Radiology. 2017;285:63–72. https://doi.org/10.1148/radiol.2017162732. In this work of Puntmann et al. the diagnostic importance of tissue characterization by T1- and T2-Mapping in early disease stages is highlighted.CrossRefPubMed

45.

Greulich S, Kitterer D, Latus J, et al. Comprehensive Cardiovascular Magnetic Resonance Assessment in Patients with Sarcoidosis and Preserved Left Ventricular Ejection Fraction. Circulation: Cardiovasc Imaging 2016:9. https://doi.org/10.1161/CIRCIMAGING.116.005022.

46.

Crouser ED, Ono C, Tran T, et al. Improved Detection of Cardiac Sarcoidosis Using Magnetic Resonance with Myocardial T2 Mapping. Am J Respir Crit Care Med. 2014;189:109–12. https://doi.org/10.1164/rccm.201309-1668LE.CrossRefPubMedPubMedCentral

47.

Yang Y, Zavodni A, Roifman I, et al. Myocardial extracellular space volume in patients with systemic sarcoidosis: quantitative measurement using a T1 mapping technique. J Cardiovasc Magn Reson. 2014;16:P279. https://doi.org/10.1186/1532-429X-16-S1-P279.CrossRefPubMedCentral

48.

Greulich S, Mahrholdt H. Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Always Look at the Bright Side of Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging. 2016;9:e004417. https://doi.org/10.1161/CIRCIMAGING.115.004417.CrossRefPubMed

49.

Treiber J, Novak D, Fischer-Rasokat U, et al. Regional extracellular volume within late gadolinium enhancement-positive myocardium to differentiate cardiac sarcoidosis from myocarditis of other etiology: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2023;25:8. https://doi.org/10.1186/s12968-023-00918-z.CrossRefPubMedPubMedCentral

50.

Bohnen S, Radunski UK, Lund GK, et al. Tissue characterization by T1 and T2 mapping cardiovascular magnetic resonance imaging to monitor myocardial inflammation in healing myocarditis. Eur Heart J Cardiovasc Imaging. 2017;18. https://doi.org/10.1093/EHJCI/JEX007.

51.

Lota AS, Gatehouse PD, Mohiaddin RH. T2 mapping and T2* imaging in heart failure. Heart Fail Rev. 2017;22:431. https://doi.org/10.1007/S10741-017-9616-5.CrossRefPubMedPubMedCentral

52.

•• Chamberlin JH, Kocher MR, Aquino G, et al. Quantitative myocardial T2 mapping adds value to Japanese circulation society diagnostic criteria for active cardiac sarcoidosis. Int J Cardiovasc Imaging. 2023;1–12. https://doi.org/10.1007/s10554-023-02863-5. This group found that incorporating T2-mapping into the diagnostic process increases the accuracy of identifying active inflammation when compared to relying solely on the JCS diagnostic criteria.

53.

Lurz P, Eitel I, Adam J, et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging. 2012;5:513–24. https://doi.org/10.1016/j.jcmg.2011.11.022.CrossRefPubMed

54.

Panopoulos S, Mavrogeni S, Vlachopoulos C, Sfikakis PP. Cardiac magnetic resonance imaging before and after therapeutic interventions for systemic sclerosis-associated myocarditis. Rheumatology (Oxford, England). 2023;62:1535–42. https://doi.org/10.1093/rheumatology/keac504.CrossRefPubMed

55.

Crouser ED, Ruden E, Julian MW, Raman SV. Resolution of abnormal cardiac MRI T2 signal following immune suppression for cardiac sarcoidosis. J Investig Med. 2016;64:1148–50. https://doi.org/10.1136/jim-2016-000144.CrossRefPubMed

56.

Slart RHJA, Glaudemans AWJM, Lancellotti P, et al. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. J Nucl Cardiol. 2018;25:298–319. https://doi.org/10.1007/s12350-017-1043-4.CrossRefPubMed

57.

Manabe O, Yoshinaga K, Ohira H, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol. 2016;23:244–52. https://doi.org/10.1007/s12350-015-0226-0.CrossRefPubMed

58.

Atterton-Evans V, Turner J, Vivanti A, Robertson T. Variances of dietary preparation for suppression of physiological 18F-FDG myocardial uptake in the presence of cardiac sarcoidosis: A systematic review. J Nucl Cardiol. 2020;27:481–9. https://doi.org/10.1007/s12350-018-1379-4.CrossRefPubMed

59.

Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–8. https://doi.org/10.2967/jnumed.111.090662.CrossRefPubMed

60.

Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol. 2017;24:1741–58. https://doi.org/10.1007/s12350-017-0978-9.CrossRefPubMed

61.

Ahmadian A, Pawar S, Govender P, et al. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. J Nucl Cardiol. 2017;24:413–24. https://doi.org/10.1007/s12350-016-0490-7.CrossRefPubMed

62.

Ahmadian A, Brogan A, Berman J, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2014;21:925–39. https://doi.org/10.1007/s12350-014-9901-9.CrossRefPubMed

63.

Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329–36. https://doi.org/10.1016/j.jacc.2013.09.022.CrossRefPubMed

64.

Dweck MR, Abgral R, Trivieri MG, et al. Hybrid Magnetic Resonance Imaging and Positron Emission Tomography With Fluorodeoxyglucose to Diagnose Active Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2018;11:94–107. https://doi.org/10.1016/j.jcmg.2017.02.021.CrossRefPubMed

65.

•• Greulich S, Gatidis S, Gräni C, et al. Hybrid Cardiac Magnetic Resonance/Fluorodeoxyglucose Positron Emission Tomography to Differentiate Active From Chronic Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2022;15:445–56. https://doi.org/10.1016/J.JCMG.2021.08.018. The hybride approach of CMR and PET-CT provides additional information for the detection of active disease status.CrossRefPubMed

66.

• Niemelä M, Uusitalo V, Pöyhönen P, et al. Incidence and Predictors of Atrial Fibrillation in Cardiac Sarcoidosis: A Multimodality Imaging Study. JACC Cardiovasc Imaging. 2022;15:1622–31. https://doi.org/10.1016/j.jcmg.2022.02.025. The group has identified that patients with atrial inflammation detected through PET-CT scans are at risk of developing atrial fibrillation in the future.CrossRefPubMed

67.

Stievenart J, Le Guenno G, Ruivard M, et al. Cardiac sarcoidosis: systematic review of the literature on corticosteroid and immunosuppressive therapies. Eur Respir J. 2022:59. https://doi.org/10.1183/13993003.00449-2021.

68.

Ning N, Guo HH, Iagaru A, et al. Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis. J Cardiac Fail. 2019;25:307–11. https://doi.org/10.1016/j.cardfail.2019.02.018.CrossRef

69.

Osborne MT, Hulten EA, Singh A, et al. Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21:166–74. https://doi.org/10.1007/s12350-013-9828-6.CrossRefPubMed

70.

Ishizuka M, Kashimura T, Watanabe M, et al. Optimal Timing of Serial 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography after Prednisolone Treatment Introduction for Cardiac Sarcoidosis. Int Heart J. 2023;64:196–202. https://doi.org/10.1536/ihj.22-406.CrossRefPubMed

71.

• Arps K, Doss J, Geiger K, et al. Incidence and Predictors of Relapse After Weaning Immune Suppressive Therapy in Cardiac Sarcoidosis. Am J Cardiol. 2023;204:249–56. https://doi.org/10.1016/j.amjcard.2023.07.088. In this study, Arps et al. discovered that the extent of late gadolinium enhancement serves as a predictor for relapse following the cessation of immunosuppressive therapy.CrossRefPubMed

72.

Waller AH, Blankstein R. Quantifying myocardial inflammation using F18-fluorodeoxyglucose positron emission tomography in cardiac sarcoidosis. J Nucl Cardiol. 2014;21:940–3. https://doi.org/10.1007/s12350-014-9921-5.CrossRefPubMed

Title: Insights of Inflammatory Heart Involvement in Cardiac Sarcoidosis – A Systemic Review
Authors: Julia Treiber
Christian W. Hamm
Samuel T. Sossalla
Andreas Rolf
Publication date: 08-05-2024
Publisher: Springer US
Keywords: Sarcoidosis
Sarcoidosis
Sudden Cardiac Death
Published in: Current Cardiovascular Imaging Reports / Issue 7/2024
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-024-09594-8

2024 ASCO Annual Meeting

Springer Medicine

Insights of Inflammatory Heart Involvement in Cardiac Sarcoidosis – A Systemic Review

Abstract

Purpose of the Review

Recent Findings

Summary

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose of the Review

Recent Findings

Summary

Please log in to get access to this content